itraconazole / Generic mfg. - LARVOL DELTA

Dose modifications of mezigdomide when coadministered with CYP3A4 inhibitors for patients with relapsed/refractory multiple myeloma (ASH 2025) - P1/2 | "Introduction: Mezigdomide (MEZI), an oral CELMoD™ agent with potent antimyeloma and immunostimulatory effects, has demonstrated encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) as monotherapy and in combination with dexamethasone/standard treatments (CC-92480-MM-001 [NCT03374085]; CC-92480-MM-002 [NCT03989414])...A phase 1 clinical drug–drug interaction (DDI) study in healthy participants evaluated MEZI as a substrate of cytochrome P450 3A4 (CYP3A4), using rifampin (strong inducer) and itraconazole (strong inhibitor)...Specifically, MEZI CL was reduced 0.15-, 0.11- and 0.38-fold when administered with posaconazole, voriconazole, and fluconazole, respectively... MEZI is a sensitive CYP3A4 substrate. Modeling and simulation provide a robust framework to guide dose adjustments and manage potential DDI risks while preserving efficacy. For pts requiring concomitant use of strong or moderate CYP3A4is, MEZI can be continued safely with dose..."

Clinical • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134) (ASH 2025) - "To date, clinical trials with the first generation Bcl-2 inhibitor, venetoclax, have shown single agent or combination activity in a variety of B-cell malignancies (chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), select Non-Hodgkin's lymphoma subtypes, multiple myeloma) and myeloid diseases (acute myeloid leukemia)...Lonitoclax has demonstrated monotherapy activity in pre-clinical models, as well as synergistic activity when combined with azacytidine, FLT3 and menin inhibitors in AML xenograft models...Pharmacokinetic AUC 0-inf was increased (3.5-fold) with food but minimally influenced by itraconazole (+3%) or PPI administration (-27%)...Lonitoclax demonstrates favorable PK and safety profiles when administered orally as a single dose of up to 800 mg, with dose-proportional increases in systemic exposure, food but not DDI or PPI effect, target engagement using the novel PAA, and no treatment-related adverse events. By using the PAA to..."

First-in-human • P1 data • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Multiple Myeloma • Small Lymphocytic Lymphoma • ANXA5 • CASP3 • CD8 • CYP3A4 • FLT3

A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis. (ASH 2025) - "This interim analysis focuses on the 7 SADcohorts (20, 100, 300 mg, 600 mg, 300 mg with food, 300 mg with food in high BMI participants, and 600with itraconazole) and the 3 MAD cohorts (600 mg QD, 300 mg BID, and 300/600 mg BID for 7 days).Results...The most frequent TEAE was nausea(Grade 1 or Grade 2, controllable with ondansetron)...Dose-proportional systemic exposure wasobserved, and target engagement was established. The safety of balomenib in both pre-clinical andclinical studies thus far suggest it will be an exceptional therapeutic to combine with other agents inKMT2A/MEN1 dependent malignancies."

Clinical • P1 data • PK/PD data • KMT2A • MEIS1 • NPM1

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document. (PubMed, Eur J Heart Fail) - "The review examines the pathophysiological mechanisms, clinical evidence, and guideline-based recommendations for several drug classes, including antidiabetic agents (e.g. thiazolidinediones, dipeptidyl peptidase-4 inhibitors), antiarrhythmics (particularly Class I and III), calcium channel blockers, non-steroidal anti-inflammatory drugs, antifungals (e.g. itraconazole, amphotericin B), macrolide antibiotics, antihypertensives (e.g. α1-blockers, centrally acting sympatholytics), neurological and psychiatric medications (e.g. carbamazepine, pregabalin, lithium), and selected anaesthetic and anticancer agents such as anthracyclines and vascular endothelial growth factor inhibitors. The goal is to empower clinicians, pharmacists and nurses to optimize HF treatment while reducing the risk of drug-induced deterioration. Awareness of these pharmacologic pitfalls is critical to improving clinical outcomes and minimizing preventable adverse events and HF hospitalizations."

Journal • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • Psychiatry

P026 Conquering rhinofacial entomophthoromycosis: a two-drug triumph. (PubMed, Br J Dermatol) - "These cases of rhinofacial entomophthoromycosis were treated successfully with oral itraconazole and a supersaturated potassium iodide two-drug regimen in challenging cases, underscoring the regimen's therapeutic potential...Tip of nose53.358.448.353.345.752.84. Philtrum61.056.455.953.154.649.5."

Journal • Gastrointestinal Disorder • Infectious Disease

P117 Treatment and investigation of head and neck dermatitis in patients with atopic dermatitis treated with biologic and small-molecule therapies: a systematic review. (PubMed, Br J Dermatol) - "Improved/resolved HND was not reported per patient, but in one trial, the median time to 75% improvement in HND was 57 days for dupilumab (n = 238) vs. 29 days for abrocitinib 200 mg...Adverse HND was also reported for tralokinumab (3 of 49, 6%) and baricitinib (two of three, 67%)...Itraconazole led to clinical improvement in all cases that recurred on withdrawal...Future studies should compare head and neck outcomes between different biologics and JAKis. This will help improve treatment decisions for patients where HND is of particular concern."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

GD06 Terbinafine-resistant Trichophyton indotineae: an analysis of confirmed cases in our regional National Health Service board. (PubMed, Br J Dermatol) - "Of the 10 positive mycological culture samples, three were terbinafine resistant (three of 10, 30%), 10 of 10 were itraconazole sensitive, seven of 10 were micoconazole sensitive, two of 10 were voriconazole sensitive and one of 10 was griseofulvin sensitive. Our findings confirm that terbinafine-resistant T. indotineae has been detected in our regional NHS board, and identified strains appeared to be sensitive in vitro to alternative antimycotics (although they may still be clinically resistant in practice). Globally, all dermatologists should be aware of this emerging organism, perform mycological testing if suspecting a dermatophytosis and liaise with local microbiology teams where terbinafine resistance is confirmed, to allow correct treatment and national monitoring."

Journal • Dermatology • Human Immunodeficiency Virus • Infectious Disease

Cardiotoxicity associated with antifungal agents: A pharmacovigilance analysis of the FDA Adverse Event Reporting System. (PubMed, Int J Clin Pharmacol Ther) - "These findings highlight that azoles and polyenes show substantial associations with CAEs, particularly for TdP/QTP and arrhythmias. Itraconazole showed a significant association with cardiac failure and cardiomyopathy, while the signal for isavuconazole was weaker than for other triazoles. No significant cardiotoxicity signals were detected for echinocandins."

Adverse events • Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

Chromoblastomycosis in an Immunocompetent Child: A Case Report. (PubMed, Cureus) - "Histopathology confirmed the presence of a brownish, dematiaceous, fungal organism with internal septations. The patient was treated with oral itraconazole and terbinafine for six months."

Journal • Infectious Disease

Evidence Based Approach of Antifungal Prophylaxis (AFP) in Hematological Malignancies (DGHO 2025) - "Ten trials with HMA monotherapy (n=1,185), 10 with HMA/venetoclax (n=956) and 4 with FLT3-inhibitors (n=273) were analyzed...No prospective RT for AFP with isavuconazole, rezafungin or olorofim are available.In pts receiving HMA therapy, IFI ranged between 1.6 and 10.3% while AFP was usually not given...In pts treated with midostaurin, two studies (n= 218 pts) reported 29 IFI (13.3%). A total of 20,753 AFP pts episodes (eps) were included since 1984 from 95 studies during CTx and 17,482 pts received AFP within a clinical trial for AFP from 1992 to 2022. Out of these, 7,586 received fluconazole (FLU), 4,080 were on trials with posaconazole (POS) or voriconazole (VOR), 1,717 received itraconazole (ITRA), 1,895 echinocandins and 1,594 amphotericin B (AmB)(AmB deoxycholate, liposomal AmB or inhalative AmB), respectively. In pts receiving novel targeted therapies (e.g."

Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology

40 Years of Preventing Fungal Infections in Hematological Malignancies - Lessons Learned from Clinical Trials with 20,753 Patients (ASH 2024) - "Out of these, 7,586 received fluconazole (FLU), 4,080 were included in trials with posaconazole (POS) or voriconazole (VOR), 1,717 received itraconazole (ITRA), 1,895 echinocandins and 1,594 amphotericin B (AmB)(AmB deoxycholate, liposomal AmB or inhalational AmB), respectively...No prospective studies for AFP with isavuconazole and new antifungal agents like rezafungin or olorofim are available...In those receiving venetoclax/HMA, AFP practices were heterogeneous and IFI incidence ranged from 5% to 16.1% (overall probable/proven IFI : n=102 (10.6%), possible IFI not reported in all studies). In pts treated with midostaurin, 2 studies (n= 218 pts) reported 29 probable/proven IFI (13.3%). In pts treated with gilteritinib, 2 studies reported 55 pts with an IFI rate of 27.2% (including possible IFI)...Despite numerous trials for prevention of IFI, only posaconazole and fluconazole proved reduction in OM rates. There is a need for prospective clinical trials addressing..."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology

A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Oncology • Solid Tumor

Calcineurin regulates morphological development, stress responses and virulence in Fonsecaea monophora. (PubMed, PLoS Negl Trop Dis) - "Our findings advance the understanding of calcineurin's role in the morphology, antifungal resistance, and virulence of F. monophora. Given that the combination of itraconazole and tacrolimus has a synergistic effect on clinical strains, we propose that targeting calcineurin in combination with itraconazole may offer an effective therapeutic approach for CBM."

Journal

CTN-03208-1: Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=112 | Completed | Sponsor: Lomond Therapeutics Holdings, Inc. | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Acute Myelogenous Leukemia

Disseminated cutaneous blastomycosis in a liver transplant recipient: A case report. (PubMed, Med Mycol Case Rep) - "We report the case of a 54-year-old female liver transplant recipient who developed blastomycosis with cutaneous and likely pulmonary involvement. She was successfully treated with posaconazole, an alternative to itraconazole with a favorable safety and interaction profile, demonstrating the therapeutic potential of posaconazole as a primary agent for blastomycosis in transplant recipients."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation

Vitamin D-Mediated Hypercalcemia in a Dog With Putative Cutaneous Pythiosis. (PubMed, Clin Case Rep) - "This case report describes the protracted diagnosis of vitamin D-mediated hypercalcemia in conjunction with cutaneous pythiosis infection. As this was not a known risk in pythiosis cases, delayed diagnosis and treatment of hypercalcemia, along with delayed diagnosis of the pythiosis infection and use of compounded itraconazole, contributed to a poor outcome."

Journal • Endocrine Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease

Epidemiology, clinical features, antifungal resistance, and prognosis of fungemia in pediatric patients. (PubMed, J Infect Dev Ctries) - "Neonates represented the highest-risk population for pediatric fungemia, with a median hospitalization duration of 37 days. Over half of the affected children (56.4%) required ICU admission. The high rate of antifungal resistance and poor prognosis underscore the urgent need for enhanced surveillance protocols and optimized antifungal stewardship in pediatric settings."

Journal • Retrospective data • Critical care • Hematological Disorders • Infectious Disease • Neutropenia • Pediatrics

Gastrointestinal Basidiobolomycosis: A Rare Fungal Disease Mimicking Colon Cancer. (PubMed, Cureus) - "The patient is currently undergoing a six-month course of oral itraconazole and, at the six-week follow-up, showed marked improvement, including weight gain and resolution of symptoms. GIB should be considered in patients from endemic areas who present with abdominal masses, eosinophilia, and a poor response to immunosuppressive therapy. Early diagnosis through deep tissue sampling enables timely initiation of antifungal treatment and may help prevent unnecessary surgical intervention."

Journal • Colon Cancer • Colorectal Cancer • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Oncology • Pain • Solid Tumor

Trichophyton indotineae: a new diagnostic and therapeutic challenge. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Dermatology

Adjunctive Laser-Based Antimicrobial Photodynamic Therapy Using Methylene Blue for Refractory Feline Sporotrichosis. (PubMed, Photodiagnosis Photodyn Ther) - "Both cats were initially treated with a combination of itraconazole and potassium iodide for a prolonged period, resulting only in partial improvement and persistence of cutaneous lesions...The first cat achieved complete clinical cure after 11 sessions and the second after 10 sessions. The successful outcome in these cases demonstrates the potential of aPDT as a promising adjuvant technique in the treatment of refractory feline sporotrichosis."

Journal • Infectious Disease

Disseminated Cutaneous, Osteoarticular, and Tubulointerstitial Sporotrichosis in an Immunosenescent and Diabetic Host: A Case Report. (PubMed, Case Rep Dermatol Med) - "This case of disseminated sporotrichosis highlights its rare occurrence in a patient with controlled diabetes and immunosenescence. Advanced diagnostics confirmed Sporothrix schenckii as the causative agent, and itraconazole treatment led to significant improvement."

Journal • Acute Kidney Injury • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology

Recurrent pyothorax in a cat caused by Candida albicans. (PubMed, JFMS Open Rep) - "Initial treatment with amphotericin B and long-term treatment with itraconazole resulted in complete and persistent clinical recovery. Pyothorax by C albicans in a cat has been described once in 1984. To the authors' knowledge, this is only the second case description, confirmed by fungal culture."

Journal • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases

Triazole Resistance and Misidentification of Aspergillus tubingensis in Southern California. (PubMed, JAMA Netw Open) - "A substantial fraction of putative A niger isolates grew at the A niger epidemiological cut-off for itraconazole (110 of 664 [15.1%])...In this cross-sectional study of Aspergillus isolates from Kaiser Permanente Southern California, A tubingensis was a prevalent but underrecognized cause of aspergillosis in Southern California. Its frequent misidentification, association with invasive infections, and triazole resistance underscore the need for improved diagnostics and species-specific epidemiological investigations."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases

Antimicrobial activity and antifungal mechanistic study of 3‑substituted oxindoles against Aspergillus niger. (PubMed, Sci Rep) - "Compound 3f displayed the highest antifungal activity (inhibition zone = 20 mm) compared with itraconazole with a final concentration of 100 µg/mL per well (30 mm)...Docking studies of compound 3f in the active sites of chitin deacetylase AngCDA (PDB ID: 7BLY) and the 1,3-β-glucan synthase (8JZN) enzymes proved its dual-target mechanism ability to inhibit the cell wall biosynthesis. These findings highlight compound 3f as a promising lead scaffold for the development of new antifungal agents targeting fungal cell wall biosynthesis."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (clinicaltrials.gov) - P3 | N=664 | Not yet recruiting | Sponsor: University of Minnesota

New P3 trial